rs3798220

A SNP in the LPA gene on chromosome 6. Its most notable genotype is C;C: 2-3x higher risk for cardiovascular events, which can be lowered by aspirin

Gene
LPA
Location
Chr 6160,540,105 (GRCh38)
Highest magnitude
2.6Worth knowing
Tested on
23andMe, AncestryDNA
Minor allele frequency
6%

Genotypes

As shown in 23andMe and AncestryDNA files.

  1. C;CMost notableBad2-3x higher risk for cardiovascular events, which can be lowered by aspirinWorth knowing · 2.6<1% of people
  2. C;TBad2-3x higher risk for cardiovascular events, which can be lowered by aspirinWorth knowing · 2.311% of people
  3. T;TGoodnormalTypical · 0.088% of people

On SNPedia: (C;C), (C;T), (T;T). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Frequency

Share of each genotype in 7 HapMap populations.

  • AverageC;C <1% C;T 11% T;T 88%
  • European ancestry (Utah)C;C 0% C;T 0% T;T 100%
  • Han Chinese (Beijing)C;C <1% C;T 18% T;T 82%
  • Japanese (Tokyo)C;C <1% C;T 16% T;T 83%
  • Yoruba (Nigeria)C;C 0% C;T 0% T;T 100%
  • African ancestry (Southwest US)C;C 2% C;T 4% T;T 95%
  • Chinese (Denver)C;C <1% C;T 19% T;T 80%
  • Mexican ancestry (Los Angeles)C;C 2% C;T 23% T;T 75%

Notes

From SNPedia

Show notes, about 390 words

rs3798220, also known as I4399M or Ile4399Met, is a SNP in the apolipoprotein(A) LPA gene that has been reported to be associated with elevated plasma lipoprotein(a) [Lp(a)] and increased cardiovascular risk, and in particular, coronary artery disease. In one study, 25,131 initially healthy Caucasian participants in the Women's Health Study were followed for ~10 years. rs3798220(C) allele carriers (3.7%) in the placebo (i.e. not receiving aspirin) group had a 2x higher risk of major cardiovascular events than non-carriers (age-adjusted hazard ratio (HR) of 2.21, CI: 1.39-3.52). Among rs3798220(C) carriers, the risk was reduced more than twofold by aspirin: for aspirin compared with placebo the age-adjusted HR was 0.44 (CI: 0.20-0.94). The risk was not significantly reduced among non-carriers (age-adjusted HR=0.91, CI: 0.77-1.08). This interaction between carrier status and aspirin allocation was significant (P=0.048). In summary, rs3798220(C) carriers had higher plasma lipoprotein(a) and had double the risk of cardiovascular events, but also benefited more from taking aspirin. In another study, compared with noncarriers, carriers of the 4399M risk allele (2.7% of controls) had an adjusted odds ratio for severe CAD of 3.14 (CI: 1.51 to 6.56), and had 5-fold higher median plasma lipoprotein(a) levels (P=0.003), leading to the conclusion that the LPA I4399M SNP is associated with severe CAD and plasma lipoprotein(a) levels. celera says rs3798220 is an independent predictor of risk for *Coronary Heart Disease in men and women *event reduction from low dose aspirin therapy in women Carriers of the rs3798220(C) have higher levels of plasma Lp(a).

C;C

http://jdmoyer.com/2013/01/28/how-do-you-prevent-heart-disease/ People carrying the C allele produce higher levels of lipoprotein(a), and have more than a twofold increased risk of heart disease. Heart disease risk for rs3798220-C carriers can be somewhat mitigated by low-dose aspirin therapy, at least in women. Estrogen HRT also lowers lipoprotein-a/Lp(a) levels. Among Bantu fishermen, higher fish intake was also associated with lower Lp(a). Why are elevated Lp(a) levels associated with coronary heart disease? Lp(a) is similar to low-density lipoprotein (LDL), which is more likely to stick to arterial walls and clog them up (while the big HDL molecules bounce around harmlessly).

Source and license

Adapted from rs3798220 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.